DiaMedica Inc  

(Public, CVE:DMA)   Watch this stock  
Find more results for DMA
0.0900
+0.0100 (12.50%)
Sep 1 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.09 - 0.09
52 week 0.04 - 0.75
Open 0.09
Vol / Avg. 120,000.00/42,316.00
Mkt cap 7.00M
P/E     -
Div/yield     -
EPS -0.06
Shares 77.78M
Beta 0.50
Inst. own     -
Sep 10, 2015
DiaMedica Inc at Rodman & Renshaw Global Investment Conference - 9:10AM EDT - Add to calendar
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -620.45% -326.94%
Return on average equity - -
CDP Score - -

Address

1 Carlson Pkwy N Ste 124
MINNEAPOLIS, MN 55447-4453
United States - Map
+1-763-2700603 (Phone)
+1-763-7104456 (Fax)

Website links

Description

DiaMedica Inc. (DiaMedica) is a development-stage biopharmaceutical company. The Company is focused on unmet diseases, including acute vascular disease of the brain, kidney and heart. The Company's focus is on acute ischemic stroke (AIS) and acute kidney injury indications. Its lead product, DM199, is a recombinant human tissue kallikrein-1 protein (rhKLK1), a therapy engineered to improve endothelial function by vasodilation and by inducing new blood vessel growth (angiogenesis). The Company is pursuing the development of DM199 in acute vascular disease of the brain, kidney and heart with AIS as the lead initiative. It has completed a Phase I b of DM199 in T2D patients. DiaMedica's recombinant form of tissue kallikrein-1 treats a spectrum of clinical scenarios where re-establishing blood flow and reducing inflammation in patients is vital to preserving organ function, such as brain, kidney and heart. The Company has not commercialized its products and has not generated any revenues.

Officers and directors

Richard D. Pilnik Independent Chairman of the Board
Age: 56
Rick Pauls President, Chief Executive Officer, Director
John Savage CPA Chief Financial Officer
David Gurvey Vice President - Finance
Mark Williams Ph.D. Vice President - Research
Dennis D. Kim M.D. Consulting Chief Medical Officer
Age: 45
James T. Parsons CPA Corporate Secretary
Michael Giuffre M.D. Independent Director
Dawson J. Reimer Independent Director
Age: 44
Thomas G. Wellner Independent Director
Age: 50